Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Summary
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rh...
Description
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rh...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source